SCHEMBL2942289

SCHEMBL2942289

CCCC(C)c1ccc(NC(=O)N(S)C(=O)c2cc3cccnc3o2)cc1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.36
MAPT P10636 4/20 0.36
POLB P06746 3/20 0.36
RAB9A P51151 6/20 0.36
NPC1 O15118 5/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 6/20 0.36
SMN1; SMN2 Q16637 5/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35
LMNA P02545 3/20 0.34
TSHR P16473 1/20 0.34
MAPK14 Q16539 1/20 0.34
UBE2M P61081 1/20 0.33
DCUN1D1 Q96GG9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2918336 0.81 ROCK1 (0.41) TP53RAB9ANPC1KMT2AMEN1
SCHEMBL2911450 0.81 ROCK1 (0.41) TP53MAPTRAB9ANPC1KMT2A
SCHEMBL2910127 0.78 TP53 (0.34) TP53MAPTPOLBRAB9ANPC1
SCHEMBL2909187 0.69 SMN1; SMN2 (0.41) TP53MAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL2918383 0.69 SMN1; SMN2 (0.41) TP53MAPTRAB9ANPC1ALDH1A1
Hydrochloric Acid SCHEMBL2910574 0.68 SMN1; SMN2 (0.41) TP53MAPTRAB9ANPC1ALDH1A1
SCHEMBL19579787 0.67 SYK (0.46) TP53MAPTRAB9ANPC1KMT2A
SCHEMBL2942288 0.67 ALDH1A1 (0.45) MAPTPOLBRAB9ANPC1KMT2A
SCHEMBL2914221 0.66 POLB (0.35) TP53MAPTPOLBSMN1; SMN2TSHR
SCHEMBL2944777 0.64 S1PR1 (0.44) MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1709047-B1 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS INC (US) 2010-09-01 EP claimed
US-7439374-B2 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2008-10-21 US claimed
JP-2007517887-A 2007-07-05 JP claimed
EP-1709047-A2 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION Achillion Pharmaceuticals, Inc. (US) 2006-10-11 EP claimed
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2005-10-13 US claimed
WO-2005067900-A2 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2005-07-28 WO claimed
EP-1709047-B1 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS INC (US) 2010-09-01 EP disclosed
US-7439374-B2 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2008-10-21 US disclosed
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication NAT1, PIGS, ADORA1 TP53 575/4885MAPT 4359/4885POLB 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.